Graves' Disease

Pipeline Programs

Companies

Clinical Trials

3 recruiting

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

SandozAustria - Kundl

1 program

CFZ533Phase 21 trial

Active Trials

NCT02713256Completed15Est. Apr 2017

Yarrow BioscienceNY - New York

1 program

Experimental: YB-101Phase 21 trial

Active Trials

NCT07682896Recruiting232Est. Sep 2029

ImmunovantDURHAM, NC

3 programs

IMVT-1402PHASE_21 trial

Active Trials

NCT07286006Enrolling By Invitation372Est. Mar 2030

NCT07018323Recruiting210Est. May 2027

NCT06727604Recruiting240Est. Jun 2028

NovartisBASEL, Switzerland

1 program

CFZ533PHASE_2

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

2027

2028

2029

2030

Yarrow BioscienceExperimental: YB-101

ImmunovantIMVT-1402

SandozCFZ533

Clinical Trials (5)

Total enrollment: 1,069 patients across 5 trials

NCT07682896 Yarrow BioscienceExperimental: YB-101

Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

Start: Jun 2026Est. completion: Sep 2029232 patients

Phase 2Recruiting

NCT07286006 ImmunovantIMVT-1402

A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)

Start: Jan 2026Est. completion: Mar 2030372 patients

Phase 2Enrolling By Invitation

NCT07018323 ImmunovantIMVT-1402

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Start: Jun 2025Est. completion: May 2027210 patients

Phase 2Recruiting

NCT06727604 ImmunovantIMVT-1402

A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease

Start: Dec 2024Est. completion: Jun 2028240 patients

Phase 2Recruiting

NCT02713256 SandozCFZ533

A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

Start: Apr 2016Est. completion: Apr 201715 patients

Phase 2Completed

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

3 actively recruiting trials targeting 1,069 patients

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.